Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Chemoprevention Reduces Risk for Esophageal Cancer

June 5th 2018

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

Dr. Ramanathan Discusses the Treatment of Pancreatic Cancer

June 5th 2018

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.

Pancreatic Cancer Survival Jumps With Postsurgical Chemo Combo

June 4th 2018

A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.

Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer

June 4th 2018

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

June 4th 2018

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

FDA Accepts Cabozantinib Application for Advanced HCC

May 30th 2018

The FDA has accepted a supplemental new drug application for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma.

Dr. Atreya Discusses Maintenance Therapy for CRC

May 29th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

FDA Delays Decision on Lenvatinib for HCC

May 25th 2018

The FDA has extended the review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma. The new action date for the supplemental new drug application is August 24, 2018.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer

May 23rd 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care

May 23rd 2018

Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

Dr. Ramanathan on Emerging Therapeutic Targets in Patients With Pancreatic Cancer

May 22nd 2018

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses emerging therapeutic targets in patients with pancreatic cancer.

Dr. O'Neil on Neuroendocrine Tumors

May 22nd 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Collisson Covers Cholangiocarcinoma and Colon Cancer Challenges

May 21st 2018

Eric A. Collisson, MD, speaks to the challenges and emerging advancements in cholangiocarcinoma and colon cancer.

Expert Calls for Smarter Clinical Trials in Pancreatic Neoplasms

May 18th 2018

Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.

Dr. Borad on the SARAH and SIRveNIB Studies in Hepatocellular Carcinoma

May 12th 2018

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.

Dr. Ahn on the Role of Immunotherapy in Treating Patients With Gastric/Gastroesophageal Cancers

May 11th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial

May 10th 2018

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

TAS-102 Improves Survival in Gastric Cancer

May 9th 2018

Findings from the phase III TAGS trial showed that TAS-102 (trifluridine/tipiracil; Lonsurf) extended overall survival in previously treated patients with metastatic gastric cancer.